Tresiba is a long-acting insulin prescribed to manage blood sugar levels in adults and children over 1 year old with type 1 and type 2 diabetes. The appropriate Tresiba dosage varies depending on ...

NovoLog is a mealtime (rapid-acting) insulin. It’s a brand-name form of insulin aspart. For type 1 diabetes, you’ll typically inject NovoLog before your meals throughout the day. For type 2 diabetes, ...

Patients with diabetes who use Abbott's FreeStyle Libre continuous glucose monitoring (CGM) systems can now better manage their blood glucose levels with a new method for leveraging the trend arrows ...

Basaglar (insulin glargine) is a brand-name drug that’s used to help manage blood sugar levels in certain people. The drug comes as a liquid solution that’s injected under your skin. It’s usually ...

In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to fasting blood glucose levels. A fixed-dose regimen of insulin efsitora alfa ...

Not everyone with type 2 diabetes has to take insulin. But if you do, you and your doctor will decide the best schedule and insulin dose for you. You may also need to figure out some dosages on your ...

ORLANDO -- Most adults with type 1 diabetes switching from an insulin pump or multiple daily injections to inhaled insulin (Afrezza) needed to increase their dose of the inhaled product to achieve ...

People with diabetes may require regular insulin doses to help them manage their blood sugar. While individuals may wish to lower their blood glucose as quickly as possible, taking multiple doses at ...

Objective — To determine the pharmacokinetic and pharmacodynamic dose-response effects of insulin glargine administered subcutaneously in individuals with type 2 diabetes. Research design and methods ...

An insulin-sensitizing drug can benefit patients with insulin resistance at lower doses than has typically been prescribed, according to a study co-authored by Paresh Dandona, MD, Ph.D., SUNY ...

LIVONIA, Mich.--(BUSINESS WIRE)--Hygieia, a digital therapeutics company for insulin therapy, announces the American Medical Association (AMA) CPT Editorial Panel has approved two new Category III ...